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Abstract
ABSTRACT: BACKGROUND: Malaria chemoprophylaxis prevents the occurrence of the symptoms of
malaria. Travellers to high-risk Plasmodium falciparum endemic areas need an effective
chemoprophylaxis. METHODS: A literature search to update the status of mefloquine as a malaria
chemoprophylaxis. RESULTS: Except for clearly defined regions with multi-drug resistance,
mefloquine is effective against the blood stages of all human malaria species, including the recently
recognized fifth species, Plasmodium knowlesi. New data were found in the literature on the
tolerarability of mefloquine and the use of this medication by groups at high risk of malaria.
DISCUSSION: Use of mefloquine for pregnant women in the second and third trimester is sanctioned
by the WHO and some authorities (CDC) allow the use of mefloquine even in the first trimester.
Inadvertent pregnancy while using mefloquine is not considered grounds for pregnancy termination.
Mefloquine chemoprophylaxis is allowed during breast-feeding. Studies show that mefloquine is a good
option for other high-risk groups, such as long-term travellers, VFR travellers and families with small
children. Despite a negative media perception, large pharmaco-epidemiological studies have shown that
serious adverse events are rare. A recent US evaluation of serious events (hospitalization data) found no
association between mefloquine prescriptions and serious adverse events across a wide range of
outcomes including mental disorders and diseases of the nervous system. As part of an in-depth analysis
of mefloquine tolerability, a potential trend for increased propensity for neuropsychiatric adverse events
in women was identified in a number of published clinical studies. This trend is corroborated by several
cohort studies that identified female sex and low body weight as risk factors. CONCLUSION: The
choice of anti-malarial drug should be an evidence-based decision that considers the profile of the
individual traveller and the risk of malaria. Mefloquine is an important, first-line anti-malarial drug but
it is crucial for prescribers to screen medical histories and inform mefloquine users of potential adverse
events. Careful prescribing and observance of contraindications are essential. For some indications,
there is currently no replacement for mefloquine available or in the pipeline.
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Abstract
Background: Malaria chemoprophylaxis prevents the occurrence of the symptoms of malaria. Travellers to high-risk
Plasmodium falciparum endemic areas need an effective chemoprophylaxis.
Methods: A literature search to update the status of mefloquine as a malaria chemoprophylaxis.
Results: Except for clearly defined regions with multi-drug resistance, mefloquine is effective against the blood
stages of all human malaria species, including the recently recognized fifth species, Plasmodium knowlesi. New data
were found in the literature on the tolerability of mefloquine and the use of this medication by groups at high risk
of malaria.
Discussion: Use of mefloquine for pregnant women in the second and third trimester is sanctioned by the WHO
and some authorities (CDC) allow the use of mefloquine even in the first trimester. Inadvertent pregnancy while
using mefloquine is not considered grounds for pregnancy termination. Mefloquine chemoprophylaxis is allowed
during breast-feeding. Studies show that mefloquine is a good option for other high-risk groups, such as long-term
travellers, VFR travellers and families with small children. Despite a negative media perception, large pharmaco-
epidemiological studies have shown that serious adverse events are rare. A recent US evaluation of serious events
(hospitalization data) found no association between mefloquine prescriptions and serious adverse events across a
wide range of outcomes including mental disorders and diseases of the nervous system. As part of an in-depth
analysis of mefloquine tolerability, a potential trend for increased propensity for neuropsychiatric adverse events in
women was identified in a number of published clinical studies. This trend is corroborated by several cohort
studies that identified female sex and low body weight as risk factors.
Conclusion: The choice of anti-malarial drug should be an evidence-based decision that considers the profile of
the individual traveller and the risk of malaria. Mefloquine is an important, first-line anti-malarial drug but it is
crucial for prescribers to screen medical histories and inform mefloquine users of potential adverse events. Careful
prescribing and observance of contraindications are essential. For some indications, there is currently no
replacement for mefloquine available or in the pipeline.
Background - the need for chemoprophylaxis
Malaria is often imported into industrialized areas clas-
sified “malaria free” due to migration and tourist travel
to malaria endemic areas. Approximately 80-90 million
travellers will visit malaria endemic areas annually. In
particular, travel to Africa has increased by 10% and
sub-Saharan Africa has seen a recent 13% growth in
international tourist arrivals [1]. Some 30,000 travellers
from industrialized countries are reported to contract
malaria each year and between 1-4% of travellers who
acquire Plasmodium falciparum malaria will die [2]. The
trend in imported malaria cases documented in North
America and Europe [3], shows an increasing proportion
caused by the life-threatening P. falciparum. Moreover,
the incidence of malaria in travellers is likely to be an
under-estimate as it does not include those diagnosed
and treated abroad and because it is estimated that
40-70% of imported malaria cases are not reported to
health authorities [2].
Travellers to sub-Saharan Africa are most at risk of
contracting malaria. Recent estimates suggest an attack
rate of 302 in 100,000 travellers to West Africa compared
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to lower rates in Southern Africa 49/100,000 and much
lower rates in Eastern Asia 5.4/100,000 and the Americas
1/100,000 [4].
Travellers who return to their country of origin to
visit friends and relatives (VFR) have been shown to
have a higher risk of acquiring malaria than regular
tourists [5]. This is particularly true of migrant VFR tra-
vellers to West Africa [6].
The overall case fatality rate of imported P. falci-
parum malaria varies from 0.6 to 3.8% [2] but may be
20% or greater in the elderly or in cases of severe
malaria even when optimally managed in modern inten-
sive care units. Case fatality rates for malaria compli-
cated by adult respiratory distress syndrome (ARDS)
often exceed 80% [7]. However, malaria infection and
associated fatalities are largely preventable. In nearly all
reported fatal cases of imported malaria, travellers failed
to use or comply with appropriate chemoprophylactic
regimens. Recent reports of fatal cases of malaria in
North America and Europe [8] highlight problems in
these areas. In nearly all fatal outcomes, patients were
using either no chemoprophylaxis or an inappropriate
regimen, had a delay or errors in the diagnosis of
malaria by physicians and laboratories, or received
incorrect initial chemotherapy.
Definitions
Malaria chemoprophylaxis can be defined as the use of
anti-malarial medication to prevent the occurrence of
the symptoms of malaria. No available drug can destroy
the sporozoites (inoculated by the Anopheles mosquito),
which remain only briefly in the bloodstream before
entering the liver. Drugs which act on the parasite in
the liver tissue are termed “causal prophylactics“, for
example, atovaquone and proguanil. Doxycycline has
only a weak causal effect. “Suppressive prophylactics“ or
blood schizontocidal drugs act in the bloodstream when
parasites invade the erythrocyctes. Most anti-malarial
drugs fall into this category, for example, mefloquine
and doxycycline.
Current guidelines for malaria chemoprophylaxis
There is a lack of international harmony in guidelines
for malaria prevention (Table 1), but almost all authori-
ties and expert groups agree that mefloquine, atova-
quone/proguanil and doxycycline are “priority” anti-
malarial medications for travellers (Figure 1) to areas of
chloroquine-resistant Plasmodium falciparum (CRPF)
[9-17]. Other possibilities for chemoprophylaxis include
the use of chloroquine with proguanil (rarely recom-
mended due to widespread chloroquine resistance) and
primaquine, only occasionally recommended for the
prophylaxis indication in Canada and the US [10,12]
(Figure 1). The choice of medication depends on the
risk of malaria at the destination, resistance, the profile
of the traveller (contra-indications, underlying health
conditions, purpose of travel such as VFR), the duration
of travel and finally cost and adherence issues. The
registration status of the anti-malarial medications is
also a factor. In Japan [17] for example, mefloquine is
the only registered anti-malarial drug (Table 1) and no
anti-malarial chemoprophylaxis is registered for children
aged less than 8 years.
The priority anti-malarials: indications, administration and
clinical use
Mefloquine is available for malaria chemoprophylaxis
since 1985 in Europe, since 1990 in the USA [18] and
has been used by more than 35 million travellers for
this indication. Mefloquine is effective in the prevention
of CRPF malaria, except in clearly defined Thai border
regions of multidrug resistance. Today, the drug is used
clinically as a 50:50 racemic mixture of the erythro iso-
mers and all clinical studies with the drug have used
this mixture. The drug is an effective schizontocide and
is active against the blood stages of all malaria species
that infect humans including the recently recognized
fifth species, Plasmodium knowlesi [19,20]. The once
weekly regimen is considered conducive to good adher-
ence. It is a priority anti-malarial for travellers to high
risk malaria endemic areas and can be used for long-
term travellers, pregnant women, breastfeeding women,
small children weighing >5 kg and is a popular choice
for families visiting friends and relatives because of its
low cost and once weekly administration. The main
drawback in chemoprophylaxis is the risk of adverse
events particularly neuropsychiatric adverse events (see
later section). The recommended adult dose for chemo-
prophylaxis is 250 mg base weekly as a single dose (US
228 mg base). Adults weighing <45 kg and children
>5 kg require a weekly dose of 5 mg base/kg.
The fixed dose combination Malarone® is 250 mg ato-
vaquone combined with 100 mg proguanil hydrochlor-
ide (or an equivalent dose based on body weight in
children) has an overall anti-malarial efficacy of circa
95% [21] and is well tolerated by travellers [22] with the
lowest frequency of adverse events. A major advantage
of this combination is its causal prophylactic activity
directed against the early liver stages of P. falciparum
allowing discontinuation of the regimen 1 week after
leaving the malarious area. The combination is not
effective against the latent stages of relapsing malaria,
such as Plasmodium vivax. Disadvantages are the high
cost of the regimen and the limited experience and
applicability in risk groups such as pregnant women,
small children (in Europe, the combination is licensed
for children >11 kg, in the US for children >5 kg) and
long-term travellers.
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Doxycycline is third priority anti-malarial and an
adult dosage of 100 mg daily is >95% effective in
malaria chemoprophylaxis and has a weak activity
against malaria liver stages. Doxycycline monohydrate
is better tolerated than the older form doxycycline
hyclate [23], which is associated with a 6% withdrawal
rate due to gastrointestinal adverse events. Serious
adverse events are rare [24]. It is similar in cost to
mefloquine. Adherence to daily doxycycline is essential
to ensure effectiveness and non-compliance is the
main reason for prophylactic failures. Doxycycline is
not recommended in pregnancy, in breast-feeding
women and in children aged less than 8 years (in the
UK in children aged less than 12 years) [9-11,13].
There are few data on the long-term use of 100 mg
doxycycline malaria prophylaxis.
Differences exist among the chemoprophylaxis regi-
mens that are licensed, recommended, and distributed
in each country. Table 1 lists the key medications
recommended for malaria chemoprophylaxis in the
USA, Canada, UK, France, Germany, Switzerland, Japan,
and Australia, and illustrates some differences among
the guidelines. Even when the same medications are
licensed and available, health authorities may differ in
their assessment of risks, leading to different recommen-
dations for the identical traveller and itinerary. In all
guidelines worldwide, mefloquine is recognized as a key
chemoprophylaxis option.
Clinical use of mefloquine versus alternative
chemoprophylactic agents
The ideal chemoprophylactic medication should be
highly effective, cause few or no adverse events, be indi-
cated for all travellers including pregnant women, nur-
sing women, small children, long-term travellers, should
be cheap and easy to use and should be registered glob-
ally for this indication. Currently no anti-malarial satis-
fies all the criteria for a “perfect” chemoprophylaxis
regimen. Table 2 shows the position of mefloquine and
other anti-malarial chemoprophylaxis regimens in terms
of applicability to risk groups. Apart from real or per-
ceived poor tolerability, mefloquine satisfies many cri-
teria and for some groups such as pregnant women,
there is no alternative. For many VFR families, who tra-
vel for long periods to high risk areas, cost can be a
major factor in the decision as to whether or not to use
chemoprophylaxis and if yes, which one. The low cost
of weekly mefloquine plays an important role and recent
research has shown that mefloquine chemoprophylaxis
for travellers to West Africa (mainly VFR travellers) can
be cost beneficial in terms of malaria cases avoided [25].
Efficacy of mefloquine prophylaxis in travellers
Mefloquine is recognized as an effective malaria chemo-
prophylaxis for travellers to high risk CRPF areas [18].
The drug is effective as a schizontocide, active against the
blood stages of all malaria species that infect humans,
Table 1 Medications licensed and recommended for malaria chemoprophylaxis by various countries
Medication approved
and available for
malaria
chemoprophylaxis
United States Canada United
Kingdom
France Germany Switzerland Japan Australia
Mefloquine licensed licensed licensed licensed licensed licensed Licensed but
not approved
for use in
children
Licensed but
not approved
for use in
children
<14 years old
Doxycycline* for age ≥8
years
for age ≥8
years
for age
≥12 years
for age
>8 years
Off Label for age
≥8 years
- for age
>8 years
Atovaquone-proguanil licensed licensed licensed licensed licensed licensed - licensed
Primaquine Only licensed
for radical
cure but is
recommended
as primary
prophylaxis in
CDC guideline
licensed - not
recommended
for primary
prophylaxis
- - not
registered
for primary
prophylaxis
not registered
for primary
prophylaxis
-
Proguanil in
combination with
chloroquine
- - licensed licensed
°
licensed licensed - licensed
Adapted from Chen L, Wilson M, Schlagenhauf [49].
+ = licensed for malaria chemoprophylaxis and available in country.
- = not licensed for malaria chemoprophylaxis or not available.
* In some countries, doxycycline is licensed for specific indications but not malaria chemoprophylaxis. In Germany it is often used for this indication but not
licensed for malaria prophylaxis “OFF LABEL” use.
° A fixed combination of chloroquine (100 mg base) and proguanil (200 mg) is available as Savarine® in France.
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Figure 1 Malaria chemoprophylaxis for risk groups.
Table 2 Current malaria chemoprophylactic regimens based on their applicability for risk groups
Drug Efficacy° Tolerability Long-term travel Pregnancy Breastfeeding Small children <8 yrs Cost*
Mefloquine +++ +§ +++ +++ +++ +++ +++
Atovaquone/Proguanil +++ +++ ++ - +++ +++ +
Doxycycline +++ +++ ++ - - - +++
Chloroquine/Proguanil + + + ++ ++ + ++
° Efficacy of less than 75% gives a score of +, efficacy over 90% gives a score of +++ (Efficacy scores valid except for limited multi-drug resistant areas on the
Thai-Cambodian and Thai-Myanmer borders).
*The lower the cost, the higher number of +, Weighting is arbitrary and can be modified to specific travellers and itineraries. In the table, emphasis is placed on
risk groups.
§ Perceived tolerability is poor but serious adverse events are rare.
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including Plasmodium knowlesi [19,20]. The first report
of mefloquine resistance came from Thailand in 1982
and this region remains a focus of resistance particularly
on the Thai-Cambodian and Thai-Burmese borders
where prophylaxis breakdown has been observed. As
reviewed by Mockenhaupt, reports of mefloquine treat-
ment or prophylactic failures have been reported from
distinct foci in Asia and to a lesser extent, from Africa
and the Amazon Basin in South America [26].
Prophylactic failures and resistance
In many geographic regions, mapping of prophylactic
failures, mainly in non-immune individuals has been
used to detect early resistance development although it
should be emphasized that prophylactic failures do not
prove resistance. Mefloquine blood concentrations of
620 ng/ml are generally considered necessary to achieve
95% prophylactic efficacy [27]. As defined by Lobel, a
prophylactic failure is defined as a confirmed P. falci-
parum infection in persons with mefloquine blood levels
in excess of this protective level. Using this definition,
an analysis of 44 confirmed P. falciparum cases,
acquired in sub-Saharan Africa showed five volunteers
with mefloquine-resistant P. falciparum malaria [27].
Other confirmed cases were attributed to poor compli-
ance and the authors concluded that prevalence of
mefloquine-resistant malaria in sub-Saharan Africa is
still low. With regard to cross-resistance, there is recent
evidence that exposure of parasite populations to anti-
malarial drug pressure may select for resistance not only
to the drug providing the pressure but also to other
novel drugs. This was shown in Northern Cameroon,
West Africa, where the detection of a high level of resis-
tance to mefloquine was attributed to cross resistance
with quinine [28], a drug that had been used in the
area. Resistance to mefloquine appears to be distinct
from chloroquine resistance, as shown by the activity of
mefloquine against CRPF and by the inefficacy of vera-
pamil to reverse mefloquine resistance. Moreover,
in vitro studies have documented an inverse relationship
between chloroquine and mefloquine resistance. Meflo-
quine resistance is associated with halofantrine resis-
tance [29] and quinine resistance [30]. Penfluridol, a
psychotropic drug has been reported to reverse meflo-
quine resistance in P. falciparum in vitro [31].
Innate resistance is still controversial and may to some
extent be explained by cross resistance to other drugs
[26]. The molecular basis of mefloquine resistance is
currently unknown but may be the result of mutation or
amplification of certain gene products, such as Pgh1, an
energy-dependent transporter encoded by the mdr
(multi-drug resistant) homolog Pfmdr1. Later studies
demonstrate that mutations in Pfmdr1 may confer
mefloquine resistance to sensitive parasites [30].
In summary mefloquine is recognized as a highly
effective malaria chemoprophylaxis for non-immune tra-
vellers to high risk areas of chloroquine-resistant Plas-
modium falciparum with the exception of clearly
defined areas of multi-drug resistance mainly limited to
Thai border areas.
Use of mefloquine in groups at high risk of malaria
Pregnancy
Falciparum malaria in a pregnant woman poses signifi-
cant risks for the mother, foetus and the neonate.
A study of imported malaria cases from 2002 showed
that 7% of imported malaria cases in the USA occurred
in pregnant women of whom only 28% reported taking
a recommended malaria chemoprophylaxis [31]. In
France, the country with the highest number of
imported malaria cases, 3-5% of all cases occur in preg-
nant women [32]. Women who have little or no immu-
nity such as non-immune travellers are prone to
episodes of severe malaria leading to stillbirths, sponta-
neous abortions or even maternal death. Foetal and
peri-natal loss is estimated to be as high as 60-70% in
non-immune women with malaria [33]. Travel by preg-
nant women or women who might become pregnant to
destinations where chloroquine resistant P. falciparum
(CRPF) malaria is transmitted should be avoided or
deferred when possible.
Travellers to areas of chloroquine resistant P. falci-
parum need effective strategies to prevent malaria. Pro-
tection against mosquito bites is essential and a
combination of protective measures including insecticide
treated bed nets and DEET-(N, N-diethyl-3-methylben-
zamide), containing repellents are considered safe in
pregnancy and are recommended although the efficacy of
these measures for pregnant women has not been
unequivocally proven. Chloroquine and proguanil can be
used by pregnant women but because chloroquine resis-
tance is widespread, this combination has limited applic-
ability. For high risk areas of chloroquine resistant
P. falciparum, an effective chemoprophylaxis is impera-
tive and the choice is a difficult one. Doxycycline is not
recommended in pregnancy mainly based on the experi-
ence that tetracyclines cross the placenta and can lead to
disturbances of skeletal growth, permanent discoloration
of teeth, corneas and lenses [34]. Due to insufficient data,
the combination atovaquone/proguanil (Malarone®) is
not recommended in pregnancy although proguanil is
widely used and considered safe in pregnancy and no ter-
atogenicity has been observed in animal studies using
atovaquone. Because of ethical and safety restrictions,
few anti-malarials have been evaluated for pregnant, non-
immune travellers [35] and a Cochrane review concluded
that reliable research about the benefits and harms of
treatments for malaria in pregnant women is scarce [36].
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Currently, therefore, mefloquine is the only option for
pregnant women who cannot defer travel and who need
an effective chemoprophylaxis when visiting chloroquine
resistant malaria endemic areas. Literature reviews and
post-marketing surveillance studies of the Roche Drug
Safety Database [32,37] have been positive for meflo-
quine use, even in the first trimester and have shown a
low birth prevalence <4.5% of congenital malformations
in women exposed to mefloquine (as Lariam®) during
pregnancy. This level is within the background popula-
tion level of congenital malformations estimated at
between 5-6% [38].
These data have allowed expert groups to recom-
mend mefloquine during pregnancy although a survey
of the recommendations made by expert groups shows
a variation in the advice given (Table 3). The WHO,
UK and Swiss guidelines [9,11,13] sanction the use of
mefloquine during pregnancy if there is travel to a
high risk area but are more restrictive in the first tri-
mester. The US and Canadian guidelines [10,12] now
allow the use of mefloquine in all trimesters by preg-
nant women who cannot defer travel and who are at
risk of contracting malaria. This decision was based on
the view that the body of evidence showing that meflo-
quine is safe in pregnancy is adequate. Furthermore,
the American and Canadian advice does not specify
the need to avoid pregnancy for three months post
exposure to mefloquine.
Breastfed infants and small children
Young children are at special risk for malaria because of
their inability to protect themselves from mosquitoes,
the difficulty in administering anti-malarial drugs and
the rapidity at which they become severely ill. Parents
and guardians must pay particular attention to insect
protection measures including repellents and treated
bed nets.
Malaria chemoprophylaxis in the very young infant is
a challenge. Although most anti-malarials taken by the
mother will be present in breast milk, the drug concen-
trations are not considered high enough to provide an
adequate protective dose for the infant.
With regard to breastfeeding, chloroquine, atova-
quone/proguanil and mefloquine are considered compa-
tible with breastfeeding. Proguanil is excreted into
human milk in small quantities and in a rat study, ato-
vaquone concentrations in milk were 30% of the concur-
rent atovaquone concentrations in the maternal plasma.
Doxycycline is not routinely recommended.
The use of chloroquine prophylaxis is allowed in very
small children but use is limited by widespread resis-
tance to the drug. Atovaquone/proguanil prophylaxis (as
paediatric tablets) can be used for children weighing
more than 11 kg in Europe and in the US for children
>5 kg according to new CDC guidelines [10]. Doxycy-
cline is for children aged >8 yrs (in the UK doxycycline
is only allowed for children aged >12 years). Mefloquine
can be used for children >5 kg. This anti-malarial is well
tolerated in children with good adherence due to simple
once weekly dosage. The drug is bitter and parents
should disguise the taste using chocolate or yoghurt.
The tablets can be easily cut or broken and this regimen
is very suitable for children who are travelling for long
Table 3 Position of expert guidelines regarding the use of mefloquine in pregnancy
Expert Group Recommendation
Manufacturer’s label. International standard prescribing
information
Mefloquine should be used during the first trimester only if the expected benefit justifies
the potential risk to the fetus. Women of childbearing potential should be advised to
practise contraception during malaria chemoprophylaxis with mefloquine and for up to 3
months thereafter. However in the case of unplanned pregnancy, malaria
chemoprophylaxis with Lariam® is not considered an indication for pregnancy termination.
UK Health Protection Agency Advisory Committee on
Malaria Prevention for UK Travellers
Mefloquine should only be used in pregnancy if the need for it is great*. Women capable
of childbearing should take contraceptive precautions while taking mefloquine and for
three months after the last dose. Having taken mefloquine inadvertently during pregnancy
is usually not viewed as an indication to terminate a pregnancy.
World Health Organisation Mefloquine can be used in the second and third trimester. Pregnancy should be avoided
for three months after use of the drug.
Centers Disease Control (CDC) (US expert group) Use is permissible in all trimesters by pregnant women traveling to areas with known CQ-
resistant P. falciparum when travel cannot be deferred. There is no clause suggesting that
pregnancy should be avoided for three months following mefloquine use.
Committee to advise on tropical medicine and travel
(CATMAT) (Canadian expert group)
Use is permissible in all trimesters by pregnant women traveling to areas with known CQ-
resistant P. falciparum when travel cannot be deferred. There is no clause suggesting that
pregnancy should be avoided for three months following mefloquine use.
SWISS working group Mefloquine should be used during the first trimester only if the expected benefit justifies
the potential risk to the foetus. Women of childbearing potential should be advised to
practise contraception during malaria chemoprophylaxis with mefloquine and for up to 3
months thereafter.
(* An electronic update of the UK guidelines states the following: “ After expert advice, mefloquine may be considered for use in the first trimester of pregnancy“
http://www.hpa.org.uk/infections/topics_az/malaria/menu.htm)
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periods of time. Mefloquine is not approved for use in
young children in Japan [17] or in Australia [16]. The
findings of the studies done in children indicate a pre-
dictable pharmacokinetic profile of mefloquine in chil-
dren, which is similar to that observed in adults [39].
The main age related difference in pharamacokinetics is
that clearance per body weight is higher in older chil-
dren aged 5-12 years compared to younger children
aged 6 to 24 months [39,40].
Long-term travellers
A review of the literature shows that 15-82% of long-
term travellers, who spend lengthy periods in Africa,
will report malaria [41]. In high-risk areas, the probabil-
ity of being infected by malarial sporozoites increases to
almost 100% when the stay in the endemic area exceeds
four weeks with an average of 10 bites per night assum-
ing that 1% of bites are infective [42]. This crude, statis-
tical extrapolation underlines the necessity for exposure
and prevention strategies during prolonged travel in
malaria-endemic areas.
The terminology “long-term” usually refers to non-
immune travellers who visit malaria endemic areas for a
period of six months or longer. Typical long-term tra-
vellers include urban expatriates (such as diplomats, IT
personnel), rural expatriates (mining workers, mission-
aries, humanitarian), military groups, Peace Corps
volunteers, students, backpackers and occupational tra-
vellers [41]. Malaria prevention for these groups pre-
sents enormous challenges and there are few data on
long-term use of anti-malarials. Studies on Peace Corps
volunteers in West Africa provide the most robust data
[27]. Some studies exist on long-term use of malaria
prophylaxis and point to adherence with medication as
a major stumbling block. Doxycycline, used for treat-
ment of skin infections for months, can also be used as
malaria prophylaxis with daily dosing, but side effects,
especially vaginal candidiasis in women and photosensi-
tivity is a problem in long-term users. Another option is
the use of daily atovaquone/proguanil. In many coun-
tries outside of North America, use of the atovaquone/
proguanil combination is limited to a period of 28 days.
Data on the long-term use of doxycycline and atova-
quone/proguanil are limited although some data are
available on the use of atovaquone/proguanil chemopro-
phylaxis for periods longer than twenty weeks [43-45].
Long-term daily dosing is considered a risk factor for
non-adherence. Mefloquine is a chemoprophylaxis regi-
men that has been adequately evaluated in the long-
term setting and is a good option if well tolerated.
There is documented long-term use of this medication
in Peace Corps groups who took mefloquine for period
of more than one year in West Africa [27] and were
effectively protected against malaria in this high risk
area, with a very low overall discontinuation rate due to
adverse events (0.9%). They also noted that the fre-
quency of reported adverse events decreased with pro-
longed use suggesting that mild symptoms are well
tolerated. Pennie and colleagues reported on the steady
state pharmacokinetics of weekly mefloquine in long-
term travellers [46] and showed that toxic accumulation
of the drug did not occur during prolonged weekly dos-
ing. Mefloquine chemoprophylaxis use is well documen-
ted in long-term travellers and if well tolerated, can be
used for prolonged periods [47]. The long half-life of
the drug allows for weekly dosing and thus good adher-
ence [48].
Performance impact of mefloquine - use of mefloquine
while flying, driving or diving
Because many reports highlighted neuropsychological
mefloquine events, concern emerged that the use of
mefloquine prophylaxis may impair performance and
precision while driving, operating machinery or for sol-
diers in combat situations. For travellers, the impact of
mefloquine on driving performance, in particular,
required clarification. A review of mefloquine clinical
toxicity studies including a study on driving perfor-
mance with alcohol challenge showed that mefloquine,
with or without small quantities of alcohol, does not
impair driving [49]. Additionally, some diving schools
prohibit the use of mefloquine although there is no
scientific basis to support this ban. These controlled stu-
dies suggest that although mefloquine is associated with
neuropsychological events in travellers, there is no per-
formance deficit in persons who tolerate the drug [49].
Malaria chemoprophylaxis for senior citizens
Older travellers are less likely to report adverse events
with mefloquine than their younger counterparts [50].
One study specifically compared tolerability in senior
travellers (>60 years) and younger travellers and found
9.7% of older travellers reported adverse events attribu-
ted to their anti-malarial medication compared to 13.6%
in the (20-59 years) age group (p < 0.05) [50].
VFR travellers
Travellers visiting friends and relatives (VFR), mainly
immigrants and their children returning to their home
country for vacations, are at particularly high risk for lar-
gely preventable infectious diseases such as malaria. In
Western Europe, there are currently 20 million foreigners
of which the majority are settled immigrants. One third
come from a country outside of Europe. Increased global
mobility and eased travel as well as the growing number of
immigrants from malaria endemic countries have contrib-
uted to increased numbers of imported malaria cases in
Europe. The immigrants from malaria endemic countries
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constitute a special risk group with high levels of malaria
importation because they visit high risk areas for pro-
longed periods, are less likely to stay in air-conditioned
hotels and often their status and financial circumstances
hinder access to malaria chemoprophylaxis [25]. Meflo-
quine offers a reasonably priced option for financially
constrained individuals or families who visit high-risk
endemic areas. A recent analysis showed that mefloquine
was cost-effective for travellers to high-risk areas to West
Africa [25].
Mefloquine and interactions
Mefloquine should not be used concomitantly with
quinine or halofantrine and other structurally related
anti-malarials or with medications that have central or
peripheral nervous system activity. These interactions
are well described in the labelling. A retrospective ana-
lysis of a database of anti-malarial tolerability data
showed that other co-medications commonly used by
travellers (such as anti-diarrhoea medication) have had
no significant clinical impact on the safety of prophy-
laxis with mefloquine [51]. Mefloquine is extensively
metabolized in the liver by CYP3A4, therefore, caution
should be exercised when mefloquine is concomitantly
administered particularly with potent CYP3A4 inhibi-
tors such as ketoconazole. The co-administration of
mefloquine with cardioactive drugs might contribute to
the prolongation of QTc intervals, although, in the
light of the information currently available, co-admin-
istration of mefloquine with such drugs is not contra-
indicated but should be monitored. Vaccination with
oral live typhoid or cholera vaccines should be com-
pleted at least three days before the first dose of
mefloquine.
Mefloquine and its metabolite are not appreciably
removed by haemodialysis [52]. No special dosage
adjustments are indicated for dialysis patients to achieve
concentrations in plasma similar to those in healthy
volunteers.
Tolerability of mefloquine and adverse events
There is considerable controversy among international
experts regarding the tolerability of mefloquine prophy-
laxis versus alternative regimens, such as doxycycline,
chloroquine/proguanil and, the combination atova-
quone/proguanil.
Adverse events can be divided into common events,
usually mild and affecting large percentages of users and
rare events, which are seen much less frequently and
often recognized only after millions of users have used
the drug. Rare events are usually not discovered in
phase III trials and rely on post-marketing surveillance,
which make the true incidence very uncertain as unre-
ported events are likely.
There is only one double blind, randomized controlled
trial [22] which compared all current malaria prophylac-
tic regimens and analysed adverse events in 623 travel-
lers randomized to atovaquone/proguanil (Malarone®),
mefloquine (Lariam®), doxycycline (Vibramycin®) and
chloroquine plus proguanil (Savarin®). Forty five percent
of chloroquine and proguanil users reported mild to
moderate adverse events, 42% of mefloquine users, 33%
of doxycycline users and 32% of atovaquone/proguanil
users. Significant adverse events (that interfered with
daily activity) were reported in 11% of mefloquine users,
12% in chloroquine plus proguanil users, 6% in doxycy-
cline users and 7% in atovaquone and proguanil users.
Thus all malaria chemoprophylaxis regimens are asso-
ciated with adverse events and many of the differences
between the arms were not significant. It should be
emphasized that an adverse event is not necessarily
attributable to the anti-malarial drug, but reflects all
intercurrent events experienced during the use of the
drug.
An overview of the studies and databases comparing
use of malaria chemoprophylactic agents in travellers
(Tables 4 and 5) shows largely disparate results due to
differing designs, definitions and methodologies and dif-
fering study populations. Regarding the reporting of any
AE, the incidence during use of mefloquine is usually
equivalent to the incidence reported for almost all che-
moprophylactic regimens. However, women, in particu-
lar, were significantly more likely to experience adverse
events [22,53,54].
Withdrawal rates
Although often a subjective report by the traveller, when
some measure of severity is applied to AE reporting, it
appears that between 11-17% of travellers using meflo-
quine and other anti-malarials are, to some extent, inca-
pacitated by adverse events. The extent of this
incapacitation is often difficult to quantify and a good
measure of the impact of adverse events is the extent of
chemoprophylaxis curtailment or withdrawal from che-
moprophylaxis. In a study of 5,120 Italian soldiers,
deployed in Somalia and Mozambique in 1992-1994, the
rate of prophylaxis discontinuation in chloroquine/pro-
guanil users was 1.5% compared with a significantly
lower rate of discontinuation in mefloquine users (0.9%)
[55]. A controlled four-arm, double-blind, study showed
intermediate withdrawal rates for mefloquine (3.9%) and
doxycycline (3.9%) versus chloroquine/proguanil (5.2%)
compared with atovaquone/proguanil which had the
lowest withdrawal rate (1.8%) [22].
The 2009 Cochrane Report
The latest Cochrane report [56] used eight controlled
trials (n = 4240 participants) to evaluate current drugs
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(mefloquine, atovaquone/proguanil, doxycycline, chloro-
quine/proguanil) used for preventing malaria in travel-
lers. No serious adverse events were reported in the
users of any chemoprophylaxis. With regard to tolerabil-
ity, the authors found that the chloroquine/proguanil
regimen was the most poorly tolerated and had the
most gastro-intestinal adverse events while atovaquone/
proguanil and doxycycline had fewer neuropsychiatric
adverse events than mefloquine. Overall the atova-
quone/proguanil combination had fewer adverse events
than mefloquine (RR 0.72), fewer gastrointestinal type
adverse events (RR 0.54) and fewer neuropsychiatric
adverse events (RR 0.86) and a better Total Mood Dis-
turbance (TMD) score compared to mefloquine. The
authors concluded however, that the quality of available
evidence on tolerability is poor and that other factors
such as cost, ease of administration, type of traveller
and itinerary are also key factors in choosing an appro-
priate anti-malarial.
Serious adverse events
These are adverse events that constitute an apparent
threat to life, which require or prolong hospitalization
or which result in severe disability. Steffen’s large cohort
study in travellers to East Africa estimated that one in
10,600 mefloquine users to have a serious adverse event
(53). The study observed five probably mefloquine asso-
ciated hospitalizations: two cases of seizures, 2 psychotic
episodes and one case of vertigo. The rate of such
events for chloroquine/proguanil users was 1/5,100 [57].
Data on serious adverse events only become available
after widespread use of the anti-malarial and data is
available for older drugs, such as mefloquine and
chloroquine.
In one retrospective cohort analysis, serious neuropsy-
chiatric AEs involving hospitalization were noted for
1:607 mefloquine users versus 1:1,181 chloroquine-
proguanil users [58].
The British army’s experience with mefloquine pro-
phylaxis found the incidence of severe neuropsychiatric
reactions to be ≤1:6,000 [59]. The most recent and com-
prehensive evaluation of serious events was a US analy-
sis of hospitalizations [48] that found no association
between mefloquine prescriptions and serious adverse
events (as measured by hospitalizations) across a wide
range of outcomes including mental disorders and dis-
eases of the nervous system.
Neuropsychiatric adverse events
This is the main area of controversy in the literature
regarding the tolerability of mefloquine. Neuropsychia-
tric disorders include two broad categories of symptoms
namely central and peripheral nervous system disorders
(including headache, dizziness, vertigo, seizures) and
psychiatric disorders (including major psychiatric disor-
ders, affective disorders, anxiety and sleep disturbances).
Table 4 Adverse events interfering with daily activity (% of users)
Study Population Mefloquine Doxycycline ° Atovaquone
Proguanil
Chloroquine
Proguanil
Phillips 1996 Australian 11.2 6.5 - -
Schlagenhauf 1996 Swiss 11.2 - - -
Barrett 1996 UK 17 - - 16
Steffen 1993 European 13 - - 16
Hogh* 2000 International - - 0.2 2.0
Overbosch* 2001 International 5.0 - 1.0 -
Schlagenhauf 2003 International 10.5 5.9 6.7 12.4
Adapted from Schlagenhauf P [18]
* stopped taking anti-malarials
° more AE with hyclate than monohydrate
Table 5 Incidence of SERIOUS# Adverse Events during Chemoprophylaxis
Report Population Mefloquine Doxycycline Atovaquone
Proguanil
Chloroquine
Proguanil
MacPhearson 1992 Canadian 1/20,000 ? ? -
Steffen 1993 European 1/11,000 ? ? 1/5000
Croft 1996 UK soldiers 1/6,000 ? ? -
Barrett 1996 UK 1/600 ? ? 1/1200
Roche Drug Safety 1997 Worldwide 1/20,000 ? ? -
Adapted from Schlagenhauf P [18]
# Hospitalization
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Lobel et al [27] found an incidence of strange dreams
(25%), insomnia (9%) and dizziness (8.4%) in Peace
Corps volunteers using long-term mefloquine prophy-
laxis similar to those reported by users of chloroquine
(corresponding incidence 26%, 6.5%, 10%). No serious
neuropsychiatric reactions were causally associated with
mefloquine use in this study. Steffen et al [57]. reported
similar findings in an analysis of tourists (n = 139,164)
returning from East Africa. Headache was observed in
6.2% of mefloquine users versus 7.6% of chloroquine/
proguanil users, and dizziness, depression and insomnia
by 7.6%, 1.8% and 4.2% of mefloquine users versus 5.5%,
1.7% and 6.3% of the chloroquine/proguanil group. In
the UK retrospective survey with telephone interviews
[58] significantly more neuropsychiatric AE were
reported by mefloquine users compared with travellers
taking the chloroquine/proguanil combination. Neurop-
sychiatric events classified as disabling were reported by
0.7% of mefloquine and 0.09% chloroquine/proguanil
users, respectively (P = 0.021). Two travellers taking
mefloquine (1:607) versus one traveller using chloro-
quine/proguanil (1:1181) were hospitalized for such
events. Controlled studies have shown a significant
excess of neuropsychiatric events in mefloquine users
versus comparators [22,59].
More recent studies have used databases of electro-
nically recorded prescriptions and diagnoses to define
mefloquine exposure and outcome. The analysis of the
UK-based General Practice Research Database [60] com-
pared the risk for psychiatric disorders during or after the
use of mefloquine with the risk of other anti-malarials;
this large study concluded that mefloquine did not
increase the first time diagnosis of depression, but may
increase the risk of psychosis and anxiety reactions. A sec-
ond large study in US service members used hospitaliza-
tion as an objective measure of morbidity and concluded
that mefloquine-prescribed personnel were at no increased
risk of hospitalization for any disorder including mental
disorders and diseases of the nervous system [48].
The precise role of anti-malarial drugs in neuropsy-
chiatric adverse events is difficult to define and the role
of travel as a catalyst for such events should be consid-
ered together with other confounding factors such as
gender predisposition and the use of recreational drugs.
The WHO recommends that mefloquine be contraindi-
cated for persons with a personal or family history of
psychiatric disorders. In terms of all AE, studies have
shown that women are significantly more likely to
experience AE [22,54,58,61-63]. This might be due to
dose-related toxicity and one study has shown an asso-
ciation between low body weight and a relatively high
risk of developing AE during malaria prophylaxis [64]. It
might be due to reporting bias, greater compliance with
prescription or to gender related differences in drug
absorption, metabolism or CNS distribution or gene
polymorphisms [53]. Reduced or split dosage in women
may provide comparable chemoprophylactic protection
and may result in improved tolerability but data are
lacking. Because of the long half-life of the drug, meflo-
quine induced neuropsychiatric adverse events may per-
sist for months, but few data are available on the
duration of such events [49]. New innovative research
has sought to find biological, neurobiological or phar-
macogenetic causes of neuropsychiatric adverse events.
This has been made possible by new techniques in neu-
robiology, neurophysiology and genetic analyses that
were hitherto unavailable in the early product life of the
drug.
Mechanisms underlying poor tolerability
Recent research in animal models proposes mechanisms
that may explain the neuropsychiatric profile of adverse
events associated with mefloquine. Some of the mechan-
isms that have been proposed to explain neuropsychia-
tric adverse events with mefloquine include disruption
of calcium homeostasis of neuronal cells, inhibition of
enzymes such as acetylcholinesterase or butylcholines-
terase, inhibition of cellular transport systems (APT-
sensitive potassium channel, P-glycoprotein), blockage
of receptors (adenosine A2A, p2x7, receptor-mediated
spontaneous inhibitory postsynaptic currents) and
blockage of intercellular channels (gap junctions) [65].
The phenomenon of “connexin blockade“ by mefloquine
(and other substances) is receiving a lot of attention in
the field of neuroscience as a possible mechanism for
certain mefloquine associated adverse events. “Connex-
ins” are neuronal gap junction proteins that occur in the
brain, lens, retina, and elsewhere. These connexins are
assigned numbers according to their molecular weight.
The connexins Cx36 and Cx43 are widely distributed in
neuronal tissue. With regard to its sensitivity to meflo-
quine, Cx36 is an important gap junction protein and is
thought to be involved in synchronizing rhythmic activ-
ity of neurons in several brain regions. Experiments in a
rat model show that mefloquine effectively blocks con-
nexin 36 which may explain the biological basis of some
of mefloquine’s side-effects such as anxiety, confusion,
dizziness and other neuropsychiatric effects [66].
A paradoxical effect of connexin 36 blockade is an exci-
tory effect on cerebral seizure-like activity (in rats and
mice) as shown recently by Voss et al [67].
Most of the studies on possible mechanisms of meflo-
quine neurotoxicity were conducted at relatively high
mefloquine concentrations in animal models such as
knockout mice or in rat brain slices and the transfer of
knowledge acquired in these studies to healthy humans
using mefloquine at chemoprophylaxis dosage still
requires the bridging of a large knowledge gap.
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The use of genetic analyses to explain a predisposition
to mefloquine neuropsychiatric events including seizures
is generating warranted interest but careful attention
must be paid to confounding factors in order to mini-
mize the chance of spurious associations.
Mefloquine crosses the blood brain barrier in a rat
model, and human data shows that there is accumula-
tion in brain tissue particularly of the (+) enantiomer
[68]. Mefloquine has two asymmetric carbon atoms and
consequently exists as two enantiomers, which are both
active against P. falciparum in vitro. A study in human
volunteers documented that the pharmacokinetic of
mefloquine is highly stereospecific. Higher plasma con-
centration, longer half-live and a higher systemic expo-
sure have been shown for the (-)-enantiomer [69].
Another study investigated the enantioselective
kinetics of mefloquine during long term prophylactic
treatment [70]. These authors showed a time dependent
kinetic behaviour as well as possible enterohepatic recir-
culation for the (-)-enantiomer and concluded that not
only the pharmacokinetic but also other aspects of the
disposition and the distribution of both enantiomers are
different. An earlier tolerability study aimed to correlate
non-serious AE occurring during routine chemoprophy-
laxis with concentrations of racemic mefloquine, its
enantiomers or the carboxylic acid metabolite [62]. The
disposition of mefloquine was found to be highly selec-
tive but neither the concentrations of enantiomers, nor
total mefloquine nor metabolite were found to be signif-
icantly related to the occurrence of non-serious AE. In
animals a wide and extensive tissue distribution of both
enantiomers has been demonstrated, with higher tissue
than plasma concentrations. The efflux transporter
P-glycoprotein (P-gp) decreases concentration of both
enantiomers in tissues such as the brain. In mice the
(+)-mefloquine enantiomer seems to be the better sub-
strate for P-gp and it has been therefore more exten-
sively excluded from the blood-brain-barrier than the
(-)-enantiomer. The importance of these differences
between both enantiomers for the pharmacological
activity is currently being researched.
Furthermore, new research shows that genes encoding
various receptors, transporters, ion channels and con-
nexins differ between the sexes [71] so that men and
women show varying disease profiles and reactions to
medications [63] and this may also partially explain the
excess of neuropsychiatric adverse events of mefloquine
in women. The controlled, double-blind studies compar-
ing mefloquine-associated adverse events with that of
the comparator regimens however provide the most
objective data [22,54,59,72,73]. Some newer studies
using objective, validated psychomotor tests and specia-
lized mood questionnaires such as the “Profile of Mood
States” which endeavour to quantify moods and feelings
[54] identify an excess of women who experience and
report neuropsychiatric type adverse events.
A role has been suggested for the concomitant use of
mefloquine and recreational drugs or an interaction
between mefloquine and large quantities of alcohol [74],
although concomitant use of small quantities of alcohol
does not appear to adversely affect tolerability. Children
tolerate mefloquine well as do elderly travellers who
report significantly fewer AE than younger counterparts
[50]. One report suggests that subjects with AE have
slower elimination of mefloquine than the population in
general. Careful screening of travellers with particular
attention to contraindications such as personal or family
history of epilepsy/seizures or psychiatric disorders,
should minimize the occurrence of serious AE. Up to
10% of the travellers who need malaria chemoprophy-
laxis may have a contraindication and women are twice
as likely as men to have such contra-indications [75].
An analysis of mefloquine prescriptions showed that
some 13.8% of prescriptions were issued to individuals
who had pre-existing contra-indications [75]. Clearly
travel health advisors need to exercise more caution. In
those with no contra-indications but where there is a
fear of adverse events, some clinicians recommend start-
ing mefloquine three weeks prior to travel to allow for
adverse event screening. Some recommend using a split
dose (a half tablet twice weekly) for low body weight
women. Anecdotal reports suggest positive experience
with this approach but no published pharmacokinetic
data is available.
Tolerability of mefloquine according to age profile of
users
Mefloquine is considered to be well tolerated in small
children where the main adverse events are of gastroin-
testinal nature, probably associated with the bitter taste
of the medication which should be disguised with cho-
colate or yoghurt.
When mefloquine (Lariam®) spontaneously reported
adverse events reported to F. Hoffmann-La Roche are
categorized by system organ class and age of the meflo-
quine user, the adverse event profile shows that the neu-
ropsychiatric adverse events dominate across all age
groups with the exception of children under two where
gastrointestinal events predominate (Table 6). Elderly
individuals report lower proportions of neuropsychiatric
events compared to the “adolescent” and “adult”
categories.
Conclusion
Mefloquine is an effective anti-malarial (except in clearly
defined areas of multi-drug resistance at Thai borders)
that has been widely used by a broad spectrum of age
groups. Based on the literature reports, studies, national
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Table 6 Adverse event (AE) profile according to age (System Organ Class as a percentage of total reported AE*)
No-SOC Abbrev INFANT
(n = 35)
(>1 mth - 2 yrs)
CHILD
(n = 212)
(>2 yrs - 12 yrs)
ADOLESCENT
(n = 233)
(>12 yrs - 17 yrs)
ADULT
(n = 9896)
(>17 yrs - 65 yrs)
ELDERLY
(n = 451)
(over 65 yrs)
01-INFEC-Total 20.00 8.00 4.30 2.34 4.65
03-BLOOD-Total 5.70 4.70 3.40 1.77 3.76
04-IMMUN-Total 5.70 0.47 0.86 0.45 0.22
05-ENDO-Total 0.00 0.47 0.00 0.16 0.22
06-METAB-Total 0.00 3.00 4.29 2.78 6,2
07-PSYCH-Total 8.50 32.50 40.30 39.48 31.04
08-NERV-Total 17.10 27.30 39.48 35.08 35.90
09-EYE-Total 2.86 5.18 6.86 6.05 4.65
10-EAR-Total 0.00 5.18 6.43 6.55 7.09
11-CARD-Total 5.70 3.70 3.86 7.21 10.64
12-VASC-Total 2.86 1.40 2.14 2.67 4.65
13-RESP-Total 17.10 2.30 5.15 4.04 7.09
14-GASTR-Total 40 25.00 29.18 22.84 29.49
15-HEPAT-Total 0.00 0.94 1.28 1.00 2.66
16-SKIN-Total 14.28 16.98 12.87 12.42 15.52
17-MUSC-Total 0.00 2.83 7.72 5.66 8.65
18-RENAL-Total 0.00 2.83 1.28 1.18 3.99
19-PREG-Total 0.00 0.00 0.86 15.05 0.00
20-REPRO-Total 0.00 0.00 2.15 1.70 0.66
21-CONG-Total 2.86 0.00 0.00 0.92 0.22
22-GENRL-Total 31.42 25.0 18.88 19.64 20.18
23-INV-Total 8.50 6.60 7.30 4.78 8.86
24-INJ&P-Total 14.28 7.50 1.72 1.23 3.54
26-SOCCI-Total 0.00 0.00 0.43 2.13 0.00
02-NEOPL-Total 0.00 0.00 0.00 0.23 0.44
25-SURG -Total 0.00 0.00 0.00 0.18 0.00
Total 100% 100% 100% 100% 100%
* Data on file - F. Hoffmann La Roche, Drug Safety Data Base, MedDRA version 12.1, cut off date August 16th, 2010
Key:
01- Infections and infestations
02- Neoplasm benign, malignant and unspecified (incl. cysts and polyps)
03- Blood and lymphatic system disorders
04- Immune system disorders
05- Endocrine disorders
06- Metabolism and nutrition disorders
07- Psychiatric disorders
08- Nervous system disorders
09- Eye disorders
10- Ear and labyrinth disorders
11- Cardiac disorders
12- Vascular disorders
13- Respiratory, thoracic and mediastinal disorders
14- Gastrointestinal disorders
15- Hepatobiliary disorders
16- Skin and subcutaneous tissue disorders
17- Musculoskeletal and connective tissue disorders
18- Renal and urinary disorders
19- Pregnancy, puerperium and perinatal conditions
20- Reproductive system and breast disorders
21- Congenital, familial and genetic disorders
22- General disorders and administration site conditions
23- Investigations
24- Injury, poisoning and procedural complications
25- Surgical and medical procedures
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and international guidelines mefloquine can be particu-
larly useful in special populations such as pregnant
women, infants and small children, as well as long-term
travellers and VFRs, in which efficacy, safety or cost-
benefit profile have been well-documented. Careful pre-
scribing of mefloquine with attention to contraindica-
tions is essential, as is a clear warning about the
potential side effects.
Because many mefloquine-associated adverse events
occur early in dosing, during the intake of the initial
three tablets, starting mefloquine prophylaxis 2-3 weeks
before departure may allow for evaluation of tolerability
to the regimen. Stopping the drug with early signs of
such events should minimize the severity and duration
of adverse events and women may consider the use of
the split dose.
Mefloquine has a pivotal position as an important
first-line anti-malarial drug and needs to be preserved.
For many of its indications, there is currently no repla-
cement available or in the pipeline.
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